| Aarkstore announce a new report "Biotech | | | | deal values and volumes over the 2003-2008 |
| M&A Strategies: Deal assessments, trends | | | | period and a geographical breakdown of target |
| and future prospects" through its vast collection | | | | and acquirer locations. |
| of market research report. | | | | • Understand the critical factors influencing |
| Biotech M&A Trends Deal assessments, | | | | M&A transactions, discover the key selection |
| trends and future prospects | | | | criteria when assessing potential biotech targets |
| M&A activity in the pharma industry | | | | and determine the main M&A payment |
| continues to gain momentum as a growing | | | | mechanisms by using this report’s |
| number of companies seek to replenish drug | | | | examination of 50 biotech M&A deals since |
| pipelines through biotechnology acquisitions. | | | | 2007. |
| M&As between biotech companies are also | | | | • Benchmark M&A strategies used to |
| growing in number, stimulated by the drive to | | | | successfully expand product portfolios and |
| strengthen product portfolios and expand | | | | geographical presence with this report’s case |
| participation in the growing global biotech market. | | | | study analysis of 5 major recent M&A deals |
| Such deal activity is expected to become an | | | | including Actelion/Axovan & CoTherix, |
| increasingly prominent feature in the biotech | | | | Antisoma/Xanthus, Forest Labs/Cerexa, Solvay |
| sector over the next few years. Over 68% of | | | | Pharma/Innogenetics, Avant Immunotherapeutics |
| respondents recent proprietary survey carried out | | | | Celldex Therapeutics. |
| for this report believe that M&A initiatives will | | | | • Evaluate the future landscape for biotech |
| be integral to the continued success of their | | | | M&A’s and discover the key influences |
| company. | | | | that will drive future biotech M&A |
| ‘Biotech M&A Trends: Deal assessments, | | | | transactions with this report’s assessment of |
| trends and future prospects’ is a new that | | | | trends in M&A combinations and therapeutic |
| analyses trends in biotech M&A deals valued | | | | area targeting in addition to the potential impact |
| below $1bn across mid/small-sized pharma and | | | | of reverse mergers. |
| biotech companies, including niche biopharma | | | | Key issues examined in this report |
| players and diagnostics/medical technology | | | | • Economic gloom is driving M&A activity. |
| businesses. Trends in the value, volume and | | | | The current economic climate has contributed to |
| geographical distribution of deals are examined | | | | an increasingly cautious investment market that |
| based on M&A activity since 2003 and a | | | | has driven trade sales by biotech investors. |
| proprietary survey reveals how over 130 industry | | | | Biotech acquistions are more attractive to pharma |
| executives perceive the future of biotech | | | | companies than complex licensing deals which can |
| M&As. This report identifies the key factors | | | | cost as much as gaining total control through |
| influencing transactions with an evaluation of over | | | | acquisition. |
| 50 recent deals, in addition to providing a | | | | • Shifting trends in acquirers and targets. |
| comprehensive case study analysis detailing the | | | | Chinese firms are an appealing target for |
| strategies behind five major M&A’s. | | | | companies seeking to access the rapidly growing |
| Some key findings from this report | | | | Asian biopharmaceutical market. Indian companies |
| • US companies accounted for 42% of | | | | are becoming aggressive acquirers, having |
| acquiring companies and 41% of targets in global | | | | accounted for 12% of deals in 2008. |
| biotech M&A deals over the 2003-2008 | | | | • Acquirer priorities. Approved or late-stage |
| period. UK companies were the second most | | | | products and technology platforms are priorities |
| active as acquirers and targets. | | | | for acquiring companies. Products in the early |
| • 4% of M&A deals since 2003 have | | | | stages of development typically attract smaller |
| been valued at more than $500m, while 70% | | | | acquisition values. |
| were for less than $100m. The average deal | | | | • Influence of personalized medicine. Pharma |
| value for the five year period was $94m. Figures | | | | firms will increasingly target diagnostic companies |
| are based upon the 378 M&A deals during | | | | as part of efforts to advance their product |
| this period for which values were disclosed. | | | | development activities with molecular techniques. |
| • Marketed products and technology access | | | | In this way, personalized medicine and targeted |
| continue to be the key drivers of M&A. Of | | | | therapies will begin to blur the boundaries between |
| recent M&A deals, 46% have been founded | | | | pharmaceuticals and diagnostics. |
| upon targets with commercialized products, while | | | | Your questions answered |
| 34% were geared to harness technology | | | | • What are the key selection criteria when |
| platforms. | | | | assessing potential biotech targets? |
| • Cash is the main payment mechanism for | | | | • How important are M&A initiatives in |
| M&A deals. Of the 50 most recent deals for | | | | relation to company success in the short to |
| which values are known, 54% were cash-only, | | | | mid-term future? |
| while a further 18% were for cash and future | | | | • Why are M&A strategies attractive to a |
| milestone payments. | | | | growing number of companies? |
| • M&A will be an important source of | | | | • What are the main challenges in M&A |
| future company growth. 45% of respondents to | | | | dealmaking and how can these be overcome? |
| a proprietary survey expect over 20% of their | | | | • How can biotech companies maximize their |
| company’s future growth to stem from | | | | value prior to an acquisition? |
| M&A. | | | | • What are the current trends in M&A |
| | | | deals valued at less than $1bn? |
| Top reasons to order your copy today | | | | • Which recently adopted M&A strategies |
| • Identify the latest trends in M&A | | | | have proven to be the most effective? |
| activity with this report’s detailed analysis of | | | | |